174 related articles for article (PubMed ID: 33588527)
1. Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial.
Koriyama Y; Hori A; Ito H; Yonezawa S; Baba Y; Tanimoto N; Ueno T; Yamamoto S; Yamamoto T; Asada N; Morimoto K; Einaru S; Sakai K; Kanazu T; Matsuda A; Yamaguchi Y; Oguma T; Timmers M; Tritsmans L; Kusakabe KI; Kato A; Sakaguchi G
J Med Chem; 2021 Feb; 64(4):1873-1888. PubMed ID: 33588527
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
[TBL] [Abstract][Full Text] [Related]
3. Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.
Pettus LH; Bourbeau MP; Bradley J; Bartberger MD; Chen K; Hickman D; Johnson M; Liu Q; Manning JR; Nanez A; Siegmund AC; Wen PH; Whittington DA; Allen JR; Wood S
J Med Chem; 2020 Mar; 63(5):2263-2281. PubMed ID: 31589043
[TBL] [Abstract][Full Text] [Related]
4. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
Novak G; Streffer JR; Timmers M; Henley D; Brashear HR; Bogert J; Russu A; Janssens L; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2020 May; 12(1):58. PubMed ID: 32410694
[TBL] [Abstract][Full Text] [Related]
6. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
7. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.
May PC; Willis BA; Lowe SL; Dean RA; Monk SA; Cocke PJ; Audia JE; Boggs LN; Borders AR; Brier RA; Calligaro DO; Day TA; Ereshefsky L; Erickson JA; Gevorkyan H; Gonzales CR; James DE; Jhee SS; Komjathy SF; Li L; Lindstrom TD; Mathes BM; Martényi F; Sheehan SM; Stout SL; Timm DE; Vaught GM; Watson BM; Winneroski LL; Yang Z; Mergott DJ
J Neurosci; 2015 Jan; 35(3):1199-210. PubMed ID: 25609634
[TBL] [Abstract][Full Text] [Related]
8. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
9. [BACE1 inhibitors for the treatment of Alzheimer disease].
Tomita T
Nihon Rinsho; 2016 Mar; 74(3):427-31. PubMed ID: 27025081
[TBL] [Abstract][Full Text] [Related]
10. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.
Timmers M; Barão S; Van Broeck B; Tesseur I; Slemmon J; De Waepenaert K; Bogert J; Shaw LM; Engelborghs S; Moechars D; Mercken M; Van Nueten L; Tritsmans L; de Strooper B; Streffer JR
J Alzheimers Dis; 2017; 56(4):1437-1449. PubMed ID: 28157093
[TBL] [Abstract][Full Text] [Related]
11. Discovery of an Extremely Potent Thiazine-Based β-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose.
Tadano G; Komano K; Yoshida S; Suzuki S; Nakahara K; Fuchino K; Fujimoto K; Matsuoka E; Yamamoto T; Asada N; Ito H; Sakaguchi G; Kanegawa N; Kido Y; Ando S; Fukushima T; Teisman A; Urmaliya V; Dhuyvetter D; Borghys H; Van Den Bergh A; Austin N; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
J Med Chem; 2019 Oct; 62(20):9331-9337. PubMed ID: 31549838
[TBL] [Abstract][Full Text] [Related]
12. Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central Aβ reduction.
Nakahara K; Mitsuoka Y; Kasuya S; Yamamoto T; Yamamoto S; Ito H; Kido Y; Kusakabe KI
Eur J Med Chem; 2021 Apr; 216():113270. PubMed ID: 33765486
[TBL] [Abstract][Full Text] [Related]
13. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.
Peters F; Salihoglu H; Rodrigues E; Herzog E; Blume T; Filser S; Dorostkar M; Shimshek DR; Brose N; Neumann U; Herms J
Acta Neuropathol; 2018 May; 135(5):695-710. PubMed ID: 29327084
[TBL] [Abstract][Full Text] [Related]
14. Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden.
Anan K; Iso Y; Oguma T; Nakahara K; Suzuki S; Yamamoto T; Matsuoka E; Ito H; Sakaguchi G; Ando S; Morimoto K; Kanegawa N; Kido Y; Kawachi T; Fukushima T; Teisman A; Urmaliya V; Dhuyvetter D; Borghys H; Austin N; Van Den Bergh A; Verboven P; Bischoff F; Gijsen HJM; Yamano Y; Kusakabe K
ChemMedChem; 2019 Nov; 14(22):1894-1910. PubMed ID: 31657130
[TBL] [Abstract][Full Text] [Related]
15. Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.
Fuchino K; Mitsuoka Y; Masui M; Kurose N; Yoshida S; Komano K; Yamamoto T; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Miyajima H; Hiroyama S; Koyabu K; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
J Med Chem; 2018 Jun; 61(12):5122-5137. PubMed ID: 29733614
[TBL] [Abstract][Full Text] [Related]
16. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
Barão S; Moechars D; Lichtenthaler SF; De Strooper B
Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
[TBL] [Abstract][Full Text] [Related]
17. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
Imbimbo BP; Watling M
Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
[No Abstract] [Full Text] [Related]
18. Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain.
Zhang L; Chen L; Dutra JK; Beck EM; Nag S; Takano A; Amini N; Arakawa R; Brodney MA; Buzon LM; Doran SD; Lanyon LF; McCarthy TJ; Bales KR; Nolan CE; O'Neill BT; Schildknegt K; Halldin C; Villalobos A
J Med Chem; 2018 Apr; 61(8):3296-3308. PubMed ID: 29356535
[TBL] [Abstract][Full Text] [Related]
19. Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease.
Chen JJ; Liu Q; Yuan C; Gore V; Lopez P; Ma V; Amegadzie A; Qian W; Judd TC; Minatti AE; Brown J; Cheng Y; Xue M; Zhong W; Dineen TA; Epstein O; Human J; Kreiman C; Marx I; Weiss MM; Hitchcock SA; Powers TS; Chen K; Wen PH; Whittington DA; Cheng AC; Bartberger MD; Hickman D; Werner JA; Vargas HM; Everds NE; Vonderfecht SL; Dunn RT; Wood S; Fremeau RT; White RD; Patel VF
Bioorg Med Chem Lett; 2015 Feb; 25(4):767-74. PubMed ID: 25613679
[TBL] [Abstract][Full Text] [Related]
20. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
